• Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
REVIEW
Year : 2018  |  Volume : 4  |  Issue : 4  |  Page : 102-108

Transarterial embolization for hepatocellular adenomas: Case report and literature review


1 Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University; Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Nanning, Guangxi, China
2 Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China
3 Department of Medicine, Section of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL, USA
4 Basic Medical College of Guangxi Medical University, Nanning, Guangxi, China

Correspondence Address:
Prof. Bang-De Xiang
Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, Guangxi
China
Prof. Le-Qun Li
Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, Guangxi
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ctm.ctm_24_18

Rights and Permissions

Hepatocellular adenoma (HCAs) is a rare benign tumor in the liver. Bleeding and malignant transformation are the two severe outcomes of HCAs. Transarterial embolization (TAE) is used to treat HCAs; however, its role in an elective setting is uncertain. Here, we report a case with HCA treated by TAE in an elective setting, followed by resection after 2 months, because of stable disease. Further, we performed a comprehensive review of PubMed database for studies published between January 2000 and June 2018 involving TAE to treat HCA. The review included 22 studies involving 1504 patients with HCA, of whom 89.4% were female. Only 171/1504 (11.4%) patients received TAE, among whom resection was avoided in 80 (46.8%) patients, of whom 31 (38.7%) were bleeding before TAE and 49 (61.3%) were not. Based on data of 115 tumors reviewed, the rate of complete and partial response were 9.6% and 74.8%, respectively, with an overall (complete + partial) response of 84.3%. No mortality or adverse side effects were noted. Therefore, both in elective setting and in the setting of bleeding, TAE can be considered safe in the management of HCAs and may be regarded as reasonable alternative management to hepatic resection.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed336    
    Printed32    
    Emailed0    
    PDF Downloaded98    
    Comments [Add]    

Recommend this journal